Wingspan, the first modern payroll platform purpose-built for contractor management, announced that it has raised $24 million in Series B funding led by Touring Capital, bringing its total capital raised to $54 million. Existing investors Andreessen Horowitz, Long Journey Ventures, Distributed Ventures, Company Ventures, and 186 Ventures also participated.

Swiftly, a leading provider of innovative retail technology tools and solutions, today announced the rollout of the largest alcohol cashback program in U.S. convenience retail, in partnership with Circle K, a global leader in convenience and mobility. Now live in more than 4,300 Circle K stores across 31 states, the program offers legal-age shoppers digital cashback rebates on beer, wine, and spirits—delivered almost instantly after purchase.

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced that the first patient has been dosed in its Phase 2/3 FALCON-HD trial evaluating SKY-0515, an investigational oral RNA splicing modulator for the treatment of Huntington's disease (HD).

Kindbody, the leading national fertility clinic network and global family-building benefits provider for employers, announced today that its Board of Directors has named David Stern as Chief Executive Officer.

Gartner, the world’s leading research and advisory company, recently named Loadsmart in its 2025 Midmarket Context: ‘Magic Quadrant for Transportation Management Systems’ report.

Tilt, the pioneering platform for leave management solutions, is thrilled to announce the successful completion of its $15 million Series B funding round.

Luna, the leading provider of in-home, in-person physical therapy (PT), is proud to celebrate its one-millionth visit since the service was launched in 2019.

Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC). Following successful DC nomination, Ipsen will be responsible for all activities. Skyhawk's unique platform accelerates building RNA-targeting small molecules across several therapeutic areas, including rare neurological diseases.